Current Understanding of Circulating Biomarkers in Pulmonary Hypertension Due to Left Heart Disease

Frontiers in Medicine

article

Noah Todd¹  Yen-Chun Lai² 

[1] Division of Pulmonary, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, United States;Department of Anatomy, Indiana University School of Medicine, United States

关键词: pulmonary hypertension;    group 2 PH;    PH-HFpEF;    HFpEF;    heart failure with preserved ejection fraction;    biomarkers;   

DOI  :  10.3389/fmed.2020.570016

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Pulmonary hypertension due to left heart disease (PH-LHD; Group 2), especially in the setting of heart failure with preserved ejection fraction (HFpEF), is the most frequent cause of PH. Despite its prevalence, no effective therapies for PH-LHD are available at present. This is largely due to the lack of a concise definition for hemodynamic phenotyping, existence of significant gaps in the understanding of the underlying pathology and the impact of associated comorbidities, as well as the absence of specific biomarkers that can aid in the early diagnosis and management of this challenging syndrome. Currently, B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are guideline-recommended biomarkers for the diagnosis and prognosis of heart failure (HF) and PH. Endothelin-1 (ET-1), vascular endothelial growth factor-D (VEGF-D), and microRNA-206 have also been recently identified as new potential circulating biomarkers for patients with PH-LHD. In this review, we aim to present the current state of knowledge of circulating biomarkers that can be used to guide future research toward diagnosis, refine specific patient phenotype, and develop therapeutic approaches for PH-LHD, with a particular focus on PH-HFpEF. Potential circulating biomarkers identified in pre-clinical models of PH-LHD are also summarized here.

【 授权许可】

CC BY